Are calcium channel blockers protective against first-dose reactions to OKT3?
Richard
E A
EA
Department of Medicine, Yale University School of Medicine, New Haven, CT 06510.
Lorber
M I
MI
Marks
W H
WH
Bia
M J
MJ
D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects*
D002121:Calcium Channel Blockers; D016853:Muromonab-CD3